Shots:

• NICE has recommended Ilumetri (tildrakizumab) as a cost-effective option for the treatment of adults patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy following its assessment submission in Aug’18
• Ilumetri (tildrakizumab) is evaluated in P-III reSURFACE 1 and 2 study in 1-800 patients > 200 sites across the globe resulted in maintaining PASI 75 in 9/10 patients @148wks. and >50% of patients reported no psoriasis after 3 doses- well tolerated with low SAEs & discontinuation rates
• Ilumetri (tildrakizumab) is a humanized immunoglobulin mAb inhibits IL-23 by binding to its p19 subunit and has received approval from the European Commission on Sep’18 and provisional approval from NICE on Mar 8- 2019

Ref: Almirall | Image: Blickfang Messebau GmbH